Cargando…
Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings
BACKGROUND: In the absence of head-to-head trials, comprehensive evidence comparing onset of efficacy of novel agents for acute treatment of migraine is lacking. This study aimed to explore the relative efficacy of lasmiditan (serotonin [5-hydroxytryptamine] 1F receptor agonist) versus rimegepant an...
Autores principales: | Polavieja, Pepa, Belger, Mark, Venkata, Shiva Kumar, Wilhelm, Stefan, Johansson, Erin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258126/ https://www.ncbi.nlm.nih.gov/pubmed/35790906 http://dx.doi.org/10.1186/s10194-022-01440-w |
Ejemplares similares
-
ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020) -
Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm
por: Johnston, Karissa M, et al.
Publicado: (2022) -
The potential of lasmiditan in migraine
por: Mecklenburg, Jasper, et al.
Publicado: (2020) -
Ubrogepant to Treat Acute Migraine in Adults
por: Edinoff, Amber N., et al.
Publicado: (2021) -
Efficacy of lasmiditan for the acute treatment of perimenstrual migraine
por: MacGregor, E Anne, et al.
Publicado: (2022)